Arcadia Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $433.92K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 6, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $1.44M | $-2.09 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | $1.10M | $-2.11 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | $901.00K | $-0.97 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 7, 2025 | During market hours | $1.30M | $0.63 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | $1.46M | $-3.26 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $1.20M | $1.90 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | During market hours | $1.22M | $-2.98 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | During market hours | $1.54M | $-1.18 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | During market hours | – | – | – |
Press releases
Announcements Arcadia Biosciences filed with the SEC
Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt Resources
Agreement terminated · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences & Roosevelt Resources Business Combination December 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
ARCADIA BIOSCIENCES (RKDA) ENTERS INTO BUSINESS COMBINATION AGREEMENT WITH ROOSEVELT RESOURCES IN ALL-STOCK TRANSACTION
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2024
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2023
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces Second-Quarter and First-Half 2023 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces Strategic Review
Results of operations · Other events · EX-99.1 to Form 8-K
Arcadia Biosciences (RKDA) Announces First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Consolidated Statements of Operations and Comprehensive Loss
Results of operations · EX-99.2 to Form 8-K
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2022 Financial Results and Business Highlights
Results of operations · EX-99 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99#2 to Form 8-K
Arcadia Biosciences (RKDA) Announces CFO Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
(In thousands, except share data)
Results of operations · EX-99.2 to Form 8-K